1

CURRICULUM VITAE FOR AZIZ NAZHA, MD CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE

AUGUST 19, 2019 PERSONAL INFORMATION Name: (Nazha, Aziz ) Date of Birth: (required): (01/02/1984) Place of Birth: Damascus, Syria Citizenship: USA Education School: Tishreen University Degree: MD Dates: (2001-2007) Post-Graduate Training Institution: Thomas Jefferson University Affiliated, Atlanticare Regional Medical Center Position: Resident, Internal Medicine Dates: (2008-2011) Institution: The University of Texas, MD Anderson Cancer Center Position: Leukemia Research Fellowship Dates: (2011-2012) Institution: Cleveland Clinic, Taussig Cancer Institute Position: Hematology and Medical Oncology Fellowship Dates: (2013-2016) Contact Information (required) Institution/Institute/Department: Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195 Office Address: 9500 Euclid Avenue Office Mail Code: CA-62 Office Number: 2164457009 Beeper: (216-2136213, #86520) Office E-mail: nazhaa@ccf.org Facsimile: Other Home Address: 32825 Rebecca Lane, Avone Lake, OH, 44012 PROFESSIONAL APPOINTMENTS (recent to oldest) Position/Rank: Director, Center of Clinical Artificial Intelligence Institution: Cleveland Clinic Dates: 1/2019 - present Position/Rank: Associate Staff Institution: Cleveland Clinic, Taussig Cancer Institute Department: Department of Hematology and Medical Oncology Dates: 7/2016 - present

2

Position/Rank: Associate Staff Institution: Cleveland Clinic, Taussig Cancer Institute Department: Translational Hematology and Oncology Research Dates: 7/2016 - present ACADEMIC APPOINTMENTS (list recent to oldest) Position/Rank: Assistant Professor of Medicine Institution: Lerner College of Medicine/Case Western Reserve University Dates: 6/2017 - present Position/Rank: Instructor of Medicine Institution: The University of Texas, MD Anderson Cancer Center Department: Joint appointment in the Internal Medicine Department/Leukemia Department Dates: 7/2012 – 6/2013 CERTIFICATION AND LICENSURE Name of Board: American Board of Internal Medicine Date of Certificate: 08/24/2011 Name of Board: American Board of Hematology Date of Certificate: 10/26/201 Name of Board: American Board of Medical Oncology Date of Certificate: 10/27/2016 Name of Board: State Medical Board of Ohio Date of Certificate: 4-2013 Licensure State/Number: 35.121541 Date Issued: Through 04/01/2020 HONORS AND AWARDS

2011 Scholastic Achievement Award, Outstanding score - internal medicine, In-training examination, AtlantiCare Regional Medical Center 2011 Resident Teacher of the Year Award, Outstanding performance, Leadership and initiative, AtlantiCare Regional Medical Center 2011 American Society of Hematology Abstract Achievement Award 53rd Annual Meeting 2012 Poster finalist, Trainee Research Day, MD Anderson Cancer Center 2012 American Society of Hematology Abstract Achievement Award 54th Annual Meeting 2012 Future Leader in Hematology for Clinical Research Award 2013 James S. and Suzanne Cyrus Scholar Award Finalist, Division of Internal Medicine Research Retreat, MD Anderson Cancer Center

3

2013 American Society of Hematology Abstract Achievement Award 55th Annual Meeting 2014 Young Investigator Travel Award, Society of Hematologic Oncology Annual Meeting 2014 Selected Mentor, American Society of Clinical Oncology Diversity Mentoring Program 2014 Cleveland Clinic Excellence in Teaching Award 2014 American Society of Hematology Abstract Achievement Award 56th Annual Meeting 2015 William E. Lower Non-Clinical Research Award, Cleveland Clinic 2015 American Society of Clinical Oncology Trainee Travel Award 2015 Cleveland Clinic Excellence in Teaching Award 2015 Advocacy Leadership Institute, American Society of Hematology 2015 Who's Who in the World 2016 (Marquis, 33rd Edition) 2015 American Society of Hematology Abstract Achievement Award 57th Annual Meeting 2016 Peskind Memorial Award for Excellence in Scientific Research, Cleveland Clinic 2016 AACR/ASCO Methods in Clinical Cancer Research Scholarship 2016 Cleveland Clinic Excellence in Teaching Award 2016 Paul Calabresi Career Development Award (NIH K12), NCI 2016 Moderator, American Society of Hematology Annual Meeting; Myelodysplastic Syndrome—Clinical Studies: Prognostic and Predictive Utility of Recurrent Somatic Mutations in Myelodysplastic Syndromes 2017 Caregiver Appreciation Award, Cleveland Clinic 2017 Next Generation Innovator Award, HemOnc Today 2018 Caregiver Appreciation Award in Teaching Medical Students, Cleveland Clinic

MEMBERSHIP IN PROFESSIONAL SOCIETIES

2011- Member, American Medical Association

2012- Member, American College of Physicians 2013- Member, American Society of Hematology 2013- Member, American Society of Clinical Oncology

4

2012- Member, Society of Hematologic Oncology PROFESSIONAL SERVICES Editorial Boards Journal: Annals of Hematology & Oncology

Dates of Service: 2016 - present Journal: Journal of Applied Hematology and Transfusion Dates of Service: 2016 – present Journal: Cancer Biology & Medicine Dates of Service: 2016 – present Journal: Cancer Treatment and Research Communications Dates of Service: 2017 – present Ad Hoc Reviewer (start year):

2012- Journal of Clinical Oncology (JCO)

2013- Clinical Lymphoma, Myeloma & Leukemia

2015- Journal of Graduate Medical Education

2016- Haematologica

2016- Leukemia Research

2016- JAMA Oncology

2016- Cancer Science

2016- American Journal of Hematology

2017- Journal of Leukocytes biology

2017- Leukemia Lymphoma

2017- Leukemia

2017- Experts review in Hematology

2017- British Journal of Hematology

2018- JCO Clinical Cancer Informatics

2018- The Oncologist

2018- Drugs

2019- Frontiers in Oncology

2019- Blood

COMMITTEE SERVICE National

5

Organization: South Western Cooperative Group (SWOG) Committee Name/Role: Leukemia Committee/Member Dates of Service: 10/2016 - present Organization: International Working Group MDS/MPN Committee Name/Role: Member Dates of Service: 05/2017 - present Organization: International Working Group MDS/MPN Committee Name/Role: Response and Prognosis Committee/Chair Dates of Service: 05/2017 - present Organization: Center for International Blood and Marrow Transplant Research Committee Name/Role: Chronic Leukemia Committee/Member Dates of Service: 12/2017 - present Organization: Center for International Blood and Marrow Transplant Research Committee Name/Role: Acute Leukemia Committee/Member Dates of Service: 12/2017 - present Organization: Center for International Blood and Marrow Transplant Research Committee Name/Role: Precision Medicine Initiatives to Optimize HCT Outcomes/Member Dates of Service: 12/2017 – present Organization: NCCN Committee Name/Role: Myelodysplastic Syndromes Guidelines Dates of Service: 12/2018 - present Cleveland Clinic Committee Name/Role: House Staff Association Committee Dates of Service: 07/2015 – 06/2016 Committee Name/Role: Transfusion and Blood Products Committee / Member Dates of Service: 07/2015 – Committee Name/Role: Leukemia Quality Control Committee / Member Dates of Service: 06/2015 – Committee Name/Role: Protocol Review & Monitoring Committee / Member Dates of Service: 10/2016 – Committee Name/Role: Business Intelligence & Enterprise Analytics Advisory Committee / Member Dates of Service: 07/2016 - Committee Name/Role: Comprehensive Cancer Center Hematopoietic and Immune Cancer biology Committee/ Member Dates of Service: 08/2017 – Committee Name/Role: APEX: Leadership and Rounding Committee / Member Dates of Service: 08/ 2017 –

6

Committee Name/Role: Business Intelligence & Enterprise Analytics / Associate Medical Director Dates of Service: 01/2019 - Committee Name/Role: Business Intelligence & Enterprise Analytics Sponsor Alignment / Member Dates of Service: 01/2019 - TEACHING ACTIVITIES Presentations

“Cracking the MDS Genome: Translating Genes into the Clinic”, Massachusetts General Hospital, Boston, MA, USA, 11-2015

“Cracking the MDS Genome: Translating Genes into the Clinic”, Cleveland Clinic, Cleveland, USA, 12-2015

“Hansel and Gretel “Crumbs versus Clones”: Do Molecular Mutations Change Our Ability for Diagnosis, Prognosis and Selection of Treatment Options for MDS?, Satellite symposium, preceding the American Society of Hematology (ASH) 58th annual meeting, San Diego, CA, USA, 12-2016

“A proposal of a Model to Predict Acute Myeloid Leukemia Progression in MDS Using Machine Learning”, International Working Group for MDS Meeting, San Diego, CA, 12-2016

“Prediction models in Chronic Myelomonocytic Leukemia”, International Working Group for MDS/MPN, Valencia, Spain, 5-2017

“ Models Heterogeneity in Chronic Myelomonocytic Leukemia”, International Working Group for MDS/MPN, Atlanta, USA, 12-2017

“ Personalized Prediction Model to Risk Stratify Patients with Therapy-Related MDS”, International Working Group for MDS, Atlanta, USA

“Why Cancer Research Needs Artificial Intelligence”, Hematopoietic and Immune Cell Biology Disease Meeting, University Hospital, Ohio, USA, 4-2018

“Why Cancer Research Needs Artificial Intelligence”, Webinar, Munich Leukemia Laboratory, Munich, Germany, 2018

Harnessing the power of Artificial Intelligence in Cancer Research, Keynote Speaker, Case Comprehensive Cancer research min-retreat, Cleveland, Ohio, USA, 2-2019

Harnessing the power of Artificial Intelligence in Myelodysplastic Syndromes, Grand Rounds, Mount Saini Hospital, New York, USA, 6-2019

Visiting Professorships

1. “The Application of AI in Drug Discovery”, Daiichi Sankyo, 3-2019 Trainees / Mentees

1. Narkhade, Mayour, MD (resident)- now Hematology and Oncology fellow at Georgetown University

2. Zarzour, Ahmed, MD (resident)- now Hematology and Oncology fellow at Northwestern

University

7

3. Abuhadra, Nour, MD (resident) -now Hematology and Oncology fellow at MD Anderson Cancer Center

4. Al-Issa, Karam, MD (resident)-now Hematology and Oncology fellow at Indiana University 5. Fahrettin Covut, MD (resident) 6. Ahed Makhoul, MD (resident) 7. Yazan Madanat, MD (Hem/Onc Fellow) 8. Ambreen Ali, MD (resident) 9. Cameron Hilton, MD (medical student) 10. Rachael Hu, MD (Hem/Onc Fellow) 11. Nathan Radakovic (medical student)

Mentees Achievements (Only significant awards and presentations)

1. Karam Al-Issa: i. Oral presentation at the American Society of Hematology Annual Meeting 2016

ii. ASH abstract Achievement Award 2016 iii. Oral presentation at the ASH Hematologic Malignancies Meeting, Chicago 20116 iv. ASH Hematologic Malignancies Abstract Achievement Award 2016 v. First place Winner: Internal Medicine Residency Program Scholarly Activity, Cleveland

Clinic

2. Cameron Hilton i. American Society of Hematology HONORS Award

ii. ASH abstract Achievement Award 2018

3. Yazan Madanat: i. Oral Presentation, Society of Hematologic Oncology meeting 2018

ii. Honorable Distinction Award for poster presentation, SOHO meeting 2018 iii. ASH abstract Achievement Award 2018

Teaching Material Produced 1. Programing and Machine learning for healthcare providers, 1-2019 2. Nazha A. Case Study in MDS/AML: Treatment of an elderly patient with AML and comorbidities.

Point of Care. 3. Nazha A. Approved and Investigational Therapies for MDS. Point of Care. Teaching Activities 2015 Internal Medicine Board Review, Internal Medicine Residency Program, Cleveland

Clinic; review hematology and medical oncology questions

8

2016- Attending physician, inpatient leukemia service; supervise residents and students who rotate through the service as well as 1 hematology and medical oncology fellow. 2 months/year, 40 hours/week 2016- Myeloproliferative/Myelodysplastic Disease Seminar; Lerner College of Medicine; reviewed questions and answers with second year medical students, 2 hours 2017- Internal Medicine Residency program. Cleveland Clinic: Introduction to Leukemia for Residents, hour 2017- Leukemia Disease Seminar; Lerner College of Medicine; Mechanisms of Leukemogenesis, second year medical students, 2 hours 2018- Genomics in 2018 “ A fellow Guide”. Hematology and Medical Oncology Fellowship program. Cleveland Clinic, 1 hour RESEARCH SUPPORT 1. K12 Career Development Award, NIH

Title: Targeting TET mutations in myelodysplastic syndromes with the combination of azacitdine and ascorbic acid. The goal of this clinical trial is to enhance the overall response to azacitidine in patients with MDS who carry TET mutations. Role: PI Percent of Effort: 100% Total Direct Cost: 115,000/year for 2 years Date: 11/01/2016-11/01/2018

2. Early Phase Clinical Research Support (EPCRS), Case Comprehensive Cancer Center

Title: Targeting TET mutations in myelodysplastic syndromes with the combination of azacitdine and ascorbic acid. Role: PI

Total Direct Cost: 100,000 Date: 7/2017- 7/2019

Investigator Initiated Trials (Principle Investigator) Funded

9

1. Phase II study of Azacitidine and Ascorbic Acid in TET2 mutated Patients with Myeloid Malignancies Role: PI Funding: Case Comprehensive Cancer Center Total Direct Cost: 100,000

2. Phase Palbociclib in Combination with CPX-351 for Newly Diagnosed Acute Myeloid Leukemia Role: PI Funding: Jazz Pharmaceutical Total Direct Cost: 660,000

3. Phase CPX-351 as Novel Therapy after Hypomethylating Agent Failure in Myelodysplastic Syndromes Role: PI Funding: Jazz Pharmaceutical Total Direct Cost: 630,000

BIBLIOGRAPHY Peer Reviewed Articles 1. Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K, Cunningham K, Luger SM, Porter

DL, Schuster S, O'Doherty U, Siegel D, Stadtmauer EA. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant. 2011 Jan;46(1):59-63. doi: 10.1038/bmt.2010.63. Epub 2010 May 3.

2. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10;119(19):4524-6. doi: 10.1182/blood-2011-10-388967. Epub 2012 Mar 19.

3. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H,

Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug;97(8):1242-5. doi: 10.3324/haematol.2012.062638. Epub 2012 Apr 24.

4. Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during

pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):86-9. doi: 10.1016/j.clml.2012.06.009. Epub 2012 Sep 14.

10

5. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov;54(11):2537-9. doi: 10.3109/10428194.2013.769537. Epub 2013 Feb 21.

6. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.

7. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M,

Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13;121(24):4867-74. doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25.

8. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S,

Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):435-40. doi: 10.1016/j.clml.2013.02.021. Epub 2013 Jun 10.

9. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha

A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 1;122(5):641-7. doi: 10.1182/blood-2013-01-477687. Epub 2013 Jun 18.

10. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L,

Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov;98(11):1686-8. doi: 10.3324/haematol.2013.090282. Epub 2013 Jun 28.

11. Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A. Omacetaxine mepesuccinate (synribo) - newly

launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct;14(14):1977-86. doi: 10.1517/14656566.2013.821464.

12. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G,

Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.

13. Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and

how?. Leuk Lymphoma. 2013 Aug 28. 14. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour

E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug 19. doi:pii: S2152-2650(13)00237-1. 10.1016/j.clml.2013.05.020.

11

15. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N,

Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F.Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2013 Oct 9. [Epub ahead of print].

16. Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013 Sep 6;3:218. doi: 10.3389/fonc.2013.00218.

17. Nazha A, Romo CG, Kantarjian H, Cortes J. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct;98(10):e131. doi: 10.3324/haematol.2013.091678.

18. Tam CS, Nazha A, Verstovsek S. Pharmacotherapy of polycythemia vera. Expert Opinion on Orphan

Drugs Dec 2013, Vol. 1, No. 12, Pages 977-985. 19. Nazha A, Jorgensen JL, Verstovsek S. Paroxysmal nocturnal hemoglobinuria is not a cause of anemia

in patients with myelofibrosis. Leuk Lymphoma. 2014 Jan 24. 20. Nazha A, Kantarjian HM, Bhatt VR, et al. Prognostic Implications of Chromosome 17 Abnormalities

in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Jan 21. pii: S2152-2650(13)00251-6. doi: 10.1016/j.clml.2013.07.009.

21. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V,

Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, et al. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jul 15. pii: S2152-2650(14)00261-4. doi: 10.1016/j.clml.2014.07.001.

22. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-

Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr;90(4):276-81. doi: 10.1002/ajh.23924.

23. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-

Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2014 Dec 24. pii: S2152-2650(14)00545-X. doi: 10.1016/j.clml.2014.12.009.

24. Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia:

Forefront of the field in 2015. Crit Rev Oncol Hematol. 2015 Mar 14. pii: S1040-8428(15)00049-9. 25. Nazha A, Seastone DJ, Keng M, Hobson S, Kalaycio M, Maciejewski JP, Sekeres MA. The Revised

International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes. Leukemia Lymphoma, 2015 Jun 19:1-3.

12

26. Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? Oncologist. 2015 Jul 20. pii: theoncologist.2015-0067.

27. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME,

Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31;5:e333. doi: 10.1038/bcj.2015.53.

28. Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima

H, Sekeres MA, Maciejewski JP. Genomic Patterns Associated with Hypoplastic Compared to Hyperplastic Myelodysplastic Syndromes. Haematologica. 2015 Aug 13. pii: haematol.2015.130112.

29. Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A , Beausoleil SA , Han Y , Carraway

HE , Nazha A, et al.Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.250.

30. Zeidan A, Sekeres MA, Garcia-Manero G, Steensma D, Zell K, Barnard J, AL-Alali N, Zimmerman

C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore S, Maciejewski J, List A, and Komrokji RS. Comparison of Risk Stratification Tools in Predicting Outcomes of Patients with Higher-Risk Myelodysplastic Syndromes Treated with Azanucleosides. Leukemia. Leukemia. 2015 Oct 14. doi: 10.1038/leu.2015.283.

31. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A,

Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau S, Martinez-Lopez J, Post SM. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell. Cancer Cell. 2015 Oct 12;28(4):486-99. doi: 10.1016/j.ccell.2015.09.001.

32. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes

J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb;91(2):227-32. doi: 10.1002/ajh.24252.

33. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern

AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22.

34. Nazha A, Gerds AT. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in

Polycythemia Vera?. Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14.

35. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K,

Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent

13

failure. Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18.

36. Nazha A, Prebet T, Gore S, Zeidan AM. Chronic myelomoncytic leukemia: Are we finally solving

the identity crisis?. Blood Rev. 2016 Apr 25. pii: S0268-960X(16)30014-5. doi: 10.1016/j.blre.2016.04.006.

37. Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio

M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016 Jun 17. doi: 10.1038/leu.2016.138.

38. Nazha A, Khoury JD, Verstovsek S, Daver N. Second line therapies in polycythemia vera: What is

the optimal strategy after hydroxyurea failure?. Crit Rev Oncol Hematol. 2016 Sep;105:112-7. doi: 10.1016/j.critrevonc.2016.06.013.

39. Nazha A, Sekeres MA. Improving Prognostic Modeling in Myelodysplastic Syndromes. Curr

Hematol Malig Rep. 2016 Aug 8.

40. Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.228.

41. Nazha A, Sekeres MA. Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons

from Sequential Mutations. Annu Rev Med. 2016 Sep 7. 42. Nazha A, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill

BT, Kalaycio M, Liu H, Pohlman B, Sobecks R, Sekeres MA, Majhail NS. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. BMT. 2016 Nov;30(11):2214-2220.

43. Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, Przychodzen B, Patel

BJ, Clemente M, Sanikommu SR, Kalaycio M, Maciejewski JP, Sekeres MA. The complexity of interpreting genomic data in patients with acute myeloid leukemia. Blood Cancer J. 2016 Dec 16;6(12):e510.

44. Al-Issa K, Nazha A. Molecular landscape in acute myeloid leukemia: where do we stand in 2016.

Cancer Biol Med. 2016 Dec;13(4):474-482. 45. Hirsch CM, Przychodzen BP, Radivoyevitch T, Patel B, Thota S, Clemente MJ, Nagata Y,

LaFramboise T, Carraway H, Nazha A, Sekeres MA, Makishima H, Maciejewski JP. Molecular features of early onset adult myelodysplastic syndrome. Haematologica. 2017 Mar 2.

46. Patel SS, Sekeres MA, Nazha A. Prognostic models in predicting outcomes in myelodysplastic

syndromes after hypomethylating agent failure. Leuk Lymphoma. 2017 Mar 28:1-8. Doi. 47. Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A,

Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, Maciejewski JP, Yang FC, Jin P, Xu M. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun. 2017 Apr 25;8:15102. Doi.

14

48. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 May 9:JCO2015662510. doi: 10.1200/JCO.2015.66.2510.

49. Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch

C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017 Dec;31(12):2815-2823.

50. Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C,

Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, Maciejewski JP. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018 Feb;59(2):416-422.

51. Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A,

Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

52. Nazha A, Bejar R. Molecular Data and the IPSS-R: How Mutational Burden Can Affect

Prognostication in MDS. Curr Hematol Malig Rep. 2017 Oct;12(5):461-467. 53. Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes. Blood Cancer J. 2017 Sep 1;7(9):e602.

54. Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C,

Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, Maciejewski JP. Origins of myelodysplastic syndromes after aplastic anemia. Blood. 2017 Oct 26;130(17):1953-1957.

55. Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V,

Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Leukemia. 2017 Sep 22. doi: 10.1038/leu.

56. Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE,

Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2017 Nov 6. doi: 10.

57. Abuhadra N, Majhail NS, Nazha A. Impact of social media for the hematologist/oncologist. Semin

Hematol. 2017 Oct;54(4):193-197. 58. Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T,

Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J. 2017 Dec 14;7(12):644.

15

59. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio

M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J Clin Oncol. 2017 Dec 18:JCO2017750232.

60. Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein

DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. J Clin Oncol. 2018 Jun 20;36(18):1889-1892. doi: 10.1200/JCO.2018.78.4074. Epub 2018 May 3.

61. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414. PubMed PMID: 30037803.

62. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 Jul 27. doi: 10.1002/ajh.25234.

63. Nazha A, Patnaik MM. Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Curr Hematol Malig Rep. 2018 Jul 31. doi: 10.1007/s11899-018-0465-7.

64. Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

65. Nazha A, Patnaik MM. Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Curr Hematol Malig Rep. 2018 Oct;13(5):341-347. 66. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X,

Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473.

67. Abuhadra N, Nazha A. Online and Social Media Resources for Patients with MDS. Curr Hematol

Malig Rep. 2018 Dec;13(6):570-575.

16

68. Nazha A. The MDS genomics-prognosis symbiosis. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):270-276.

69. Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma. 2019 Jan 8:1-4. doi: 10.1080/10428194.2018.1543885.

70. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2.

71. Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M,

Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2019 Jan 17. doi: 10.1038/s41409-019-0444-1.

Edited Books, Monographs or Journal Volumes 1. Nazha A. Myelodysplastic Syndromes. Springer, currently the book is under development. Invited, Non-Peer Reviewed (author(s), title of article, journal and year, volume, pages) 1. Book Chapters 1. Zeidan A, Nazha A, Acute Promyleocytic Leukemia. In: Emadi, A and Karp JE. Acute Leukemia. New

York: Demos Medical Publishing; 2017: In Press

Audio/Video/CD-Rom, etc. (artist, title of work, date, medium) 1. Abstracts 1. Aziz Nazha, Dan T. Vogl, Una O'Doherty, Patricia Mangan, Kathleen Cunningham, Selina Luger,

David L. Porter, Stephen J. Schuster, Marie Gardler, Mary Sell, Don L. Siegel, Edward A Stadtmauer. “The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma.” [Oral and Poster] Blood 2010; 116:2252a.

2. Aziz Nazha, Zeev Estrov, Jorge E. Cortes, Sherry Pierce, Hagop M. Kantarjian, Srdan Verstovsek. “Prognostic Implications and Clinical Characteristics Associated with Bone Marrow Fibrosis in Patients with Myelofibrosis.” [Oral and Poster] Blood 2011; 118:2824a.

17

3. Aziz Nazha, Jorge E. Cortes, Zeev Estrov, Sherry Pierce, Hagop M. Kantarjian, Srdan Verstovsek.

“Clinical Significance of Bone Marrow Fibrosis in Patients with Polycythemia Vera.” [Oral and Poster] Blood 2011; 118:1495a.

4. Aziz Nazha, Vijaya R Bhatt, Graciela Nogueras-Gonzalez, Tapan Kadia, Jorge E. Cortes, Naval Daver, Guillermo Garcia-Manero, Hagop M. Kantarjian, Gautam Borthakur. “Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics.” [Oral and Poster] Blood 2011; 118:149a.

5. Aziz Nazha, Jorge E. Cortes, Stefan Faderl, Sherry Pierce, Guillermo Garcia-Manero, Susan O'Brien, Alessandra Ferrajoli, Tapan Kadia, Gautam Borthakur, Rajyalakshmi Luthra, Hagop M. Kantarjian, Farhad Ravandi. “Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,” [Oral and Poster] Blood 2011; 118:3557a.

6. Aziz Nazha, Elias Jabbour, Jorge E. Cortes, Susan O'Brien, Jenny Shan, Guillermo Garcia-

Manero, Alfonso Quintas-Cardama, Hagop M. Kantarjian. “EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),” [Oral and Poster] Blood 2011; 118:3769a.

7. Aziz Nazha, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Elias Jabbour,

Gautam Borthakur, Tapan Kadia, Marina Konopleva, Jorge E. Cortes, Alessandra Ferrajoli, Steven M. Kornblau, Michael Andreeff, Min Du, Mark Brandt, Stefan Faderl. “Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2011; 118:1550a.

8. Aziz Nazha, Loretta A Williams, Hagop M. Kantarjian, Patricia S Ault, Araceli Garcia-Gonzalez,

Janet L Williams, Alexandra Probst, Susan O'Brien, Elias Jabbour, Alfonso Quintas-Cardama, Quiling Shi, Charles S Cleeland, Jorge E. Cortes. “Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),” [Oral and Poster] Blood 2011; 118:3785a.

9. Aziz Nazha, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia-Manero, Tapan M.

Kadia, Stefan Faderl, Zeev Estrov, Elias Jabbour, Alfonso Quintas-Cardama, Farhad Ravandi, Jorge E. Cortes. “A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).” [Oral and Poster] Blood 2012; 120:3587a.”

10. Aziz Nazha, Hagop M. Kantarjian, Preetesh Jain, Elias J. Jabbour, Alfonso Quintás-Cardama,

Rajyalakshmi Luthra, Lynne V. Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry A. Pierce, Susan O'Brien, Jorge E. Cortes. “Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs).” [Oral and Poster] Blood 2012; 120:3757a.

18

11. Naveen Pemmaraju, Deborah Thomas, Hagop M. Kantarjian, Jorge E. Cortes, John T Manning, L. Jeffrey Medeiros, Susan O'Brien, Naval G. Daver, Aziz Nazha, Sherry A. Pierce, Guillermo Garcia-Manero, Elias J. Jabbour, Stefan Faderl. “Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm.” [Oral and Poster] Blood 2012; 120:3554a.

12. Paolo Strati, Hagop M. Kantarjian, Jorge E. Cortes, Farhad Ravandi, Naveen Pemmaraju,

Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Aziz Nazha, Gautam Borthakur, Stefan Faderl, Alfonso Quintás-Cardama, Naval G. Daver. “Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21.” [Oral and Poster] Blood 2012; 120:1488a.

13. Aziz Nazha, Carlos E. Bueso-Ramos, Stefan Faderl, Elihu H. Estey, Susan M. O'Brien, Michael

Farnandez, Martin Nguyen, Charles Koller, Emil Freireich, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi. “Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.” [Oral and Poster] Blood 2012; 120:2616a.

14. Aziz Nazha, Hagop M. Kantarjian, Jorge E. Cortes, Stefan Faderl, Sherry A. Pierce, Naval G.

Daver, Naveen Pemmaraju, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Alfonso Quintas-Cardama, Guillermo Garcia-Manero. “Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy.” [Oral and Poster] Blood 2012; 120:4928a.

15. Preetesh Jain, Hagop M. Kantarjian, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, Ohad

Benjamini, Sherry A. Pierce, Marylou Cardenas-Turanzas, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes. “Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib).” [Oral and Poster] Blood 2012; 120:70a.

16. Preetesh Jain, Hagop M. Kantarjian, Stefan Faderl, Keyur P. Patel, Guillermo Garcia Manero,

Ohad Benjamini, Gautam Borthakur, Naveen Pemmaraju, Tapan M. Kadia, Naval G. Daver, Aziz Nazha, Rajyalakshmi Luthra, Sherry A. Pierce, Jorge E. Cortes, Farhad Ravandi. “Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.” [Oral and Poster] Blood 2012; 120:2484a.

17. Syed M. Kazmi, Hagop M. Kantarjian, Kathy M. Tran, Jorge E. Cortes, Farhad Ravandi, Gautam

Borthakur, Elias J. Jabbour, Stefan Faderl, Guillermo Garcia-Manero, Tapan M. Kadia, Naval Daver, Sherry A. Pierce, Aziz Nazha, Alfonso Quintas-Cardama, Naveen Pemmaraju. “Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.” [Oral and Poster] Blood 2012; 120:2587a.

18. Aziz Nazha, Farhad Ravandi, Hagop M. Kantarjian, Xuelin Huang, Sangbum Choi, Guillermo

Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Jorge

19

E. Cortes, Alessandra Ferrajoli, Steven M. Kornblau, Michael Andreeff, Zeev Estrov, Naval G. Daver, Naveen Pemmaraju, Min Du, Mark Brandt, Stefan Faderl. “Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2012; 120:43a.

19. Miguel Gallardo, Hun Ju Lee, Xiaorui Zhang, Aziz Nazha, Laura R. Pageon, Steven M. Kornblau,

Alfonso Quintás-Cardama, Sean M. Post. “hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia.” [Oral and Poster] Blood 2013; 122:226a.

20. Aziz Nazha, Hagop M. Kantarjian, Farhad Ravandi, Xuelin Huang, Xuemei Wang, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Jennie Feliu, Stefan H. Faderl. “Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients.” [Oral and Poster] Blood 2013; 122:3948a.

21. Paolo Strati, Hagop M Kantarjian, Aziz Nazha, Gautam Borthakur, Naval G. Daver, Tapan M.

Kadia, Zeev Estrov, Guillermo Garcia-Manero, Trivikram Rajkhowa, Farhad Ravandi, Menda Durand, Mark Levis, Jorge E. Cortes. “Early Results of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome.” [Oral and Poster] Blood 2013; 122:3949a.

22. Michael K. Keng, Surbhi Sidana, Sudipto Mukherjee, Paul Elson, David J. Seastone, Aziz Nazha,

Amanda L. Maggiotto, CCRP, Madeline J. Schaub, Candice M. Wenzell, BCOP, Anjali S. Advani, Matt Kalaycio, Mikkael A. Sekeres. “The Degree and Effect Of Weight Loss In Acute Myeloid Leukemia Patients Receiving Induction and Post-Remission Chemotherapy.” [Oral and Poster] Blood 2013; 122:3889a.

23. Aziz Nazha, Sudipto Mukherjee, Ramon V. Tiu, Yogen Saunthararajah, Michael K. Keng, David

J. Seastone, Sean Hobson, Anjali S. Advani, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “The Revised International Prognostic Scoring System (IPSS-R) Is Not Predictive Of Survival In Patients With Secondary Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2013; 122:1524a.

24. Aziz Nazha, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi, Gautam

Borthakur, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Darla Miller, Stefan H. Faderl. “Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy.” [Oral and Poster] Blood 2013; 122:1525a.

25. Aziz Nazha, Hagop M. Kantarjian, Elias Jabbour, Courtney D. DiNardo, Gautam Borthakur,

Naval G. Daver, Stefan H. Faderl, Jing Ning, Wei Qiao, Farhad Ravandi, Tapan M. Kadia, Sherry R. Pierce, Jorge E. Cortes, Guillermo Garcia-Manero. “Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy.” [Oral and Poster] Blood 2013; 122:2788a.

20

26. Naveen Pemmaraju, Dhaval Shah, Hagop M Kantarjian, Verena Wagner, Robert Z. Orlowski,

Guillermo Garcia-Manero, Farhad Ravandi, Sherry Pierce, Koichi Takahashi, Naval G. Daver, Aziz Nazha, Srdan Verstovsek, Elias J. Jabbour, Marcos J de Lima, Richard E Champlin, Jorge E. Cortes, Muzaffar H. Qazilbash. “Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2013; 122:1424a.

27. Aziz Nazha, Hagop M. Kantarjian, Farhad Ravandi, Huang Xuelin, Sangbum Choi, Guillermo

Garcia-Manero, Elias Jabbour, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Jorge E. Cortes, Alessandra Ferrajoli, Steven M. Kornblau, Michael Andreeff, Min Du, Mark Brandt, Stefan H. Faderl. “Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2013; 122:1451a.

28. Naval G. Daver, Kiran Naqvi, Tapan M. Kadia, Courtney D. DiNardo, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naveen Pemmaraju, Mark Brandt, Susan O'Brien, Guillermo Garcia-Manero, Sherry R. Pierce, Elias Jabbour, Jorge E. Cortes, Hagop M. Kantarjian. “Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age.” [Oral and Poster] Blood 2013; 122:1530a.

29. Mingjia Li, Aziz Nazha, Paul Elson, Sean Hobson, Mikkael A. Sekeres, Matt E. Kalaycio, Ronald

M. Sobecks, Aaron Gerds, Betty K. Hamilton, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani. “A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients.” [Oral and Poster] Blood 2014; 124:5252a.

30. Aziz Nazha, David J. Seastone, Priyanka A. Pophali, Tomas Radivoyevitch, Hetty E. Carraway,

Anjali S. Advani, Matt E. Kalaycio, Gina Rupp, Kristin Colaluca, Bartlomiej P. Przychodzen, Hideki Makishima, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype.” [Oral and Poster] Blood 2014; 124:1054a.

31. David J. Seastone, Aziz Nazha, Priyanka A. Pophali, Moshe C. Ornstein, Hetty E. Carraway,

Anjali S. Advani, Aaron T. Gerds, Matt E. Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines.” [Oral and Poster] Blood 2014; 124:1290a.

32. Aziz Nazha, David J. Seastone, Tomas Radivoyevitch, Aaron T. Gerds, Sudipto Mukherjee, Hetty

E. Carraway, Anjali S. Advani, Matt E. Kalaycio, Gina Rupp, Kristin Colaluka, Sean Hobson, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2014; 124:168a.

33. Aziz Nazha, Tomas Radivoyevitch, David J. Seastone, Brittney Dienes, Bartlomiej P.

Przychodzen, Jennifer S. Carew, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Matt E. Kalaycio, Sean Hobson, Gina Rupp, Kristin Colaluca, Aaron T. Gerds, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Differences in Genomic Patterns and Clinical Outcomes

21

Between African-American and White Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2014; 124:3274a.

34. Aziz Nazha, Rami S. Komrokji, Guillermo Garcia-Manero, John Barnard, Cassie Zimmerman, Al

Ali Najla, Gail J. Roboz, David P. Steensma, Amy E. DeZern, Elias Jabbour, Sangmin Lee, Molly D. Greenberg, Alan F. List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure.” [Oral and Poster] Blood 2014; 124:3275a.

35. Aziz Nazha, David J. Seastone, Tomas Radivoyevitch, Brittney Dienes, Bartlomiej Przychodzen,

Sean Hobson, Sudipto Mukherjee, Hetty E. Carraway, Jennifer S. Carew, Anjali S. Advani, Aaron T. Gerds, Hideki Makishima, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. “Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2014; 124:4603a.

36. Eric Padron, Guillermo Garcia-Manero, Mrinal M. Patnaik, Raphael Itzykson, Terra Lasho, Aziz Nazha, Raajit K. Rampal, Matias Eugenio Sanchez, Elias Jabbour, Najla H Al Ali, Zachary Thompson, Ji-Hyun Lee, Simona Colla, Pierre Fenaux, Hagop M. Kantarjian, Sally Killick, Mikkael A. Sekeres, Alan F. List, Francesco Onida, Rami S. Komrokji, Ayalew Tefferi, Eric Solary. “An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies.” [Oral and Poster] Blood 2014; 124:530a.

37. Anjali S. Advani, Paul Elson, Matt E. Kalaycio, Sudipto Mukherjee, Aaron T. Gerds, Betty K. Hamilton, Sean Hobson, Arian Smith, Mary Lynn Rush, Samjhana Bogati, Monique Biggins, Eric D. Hsi, Hien K. Duong, Edward A. Copelan, Frederic J. Reu, Yogen Saunthararajah, Aziz Nazha, Hideki Makishima, Bartlomiej Przychodzen, Brittney Dienes, Jaroslaw P. Maciejewski, Jennifer S Carew, Hetty E. Carraway, Mikkael A. Sekeres. “Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial” [Oral and Poster] Blood 2014; 124:978a.

38. Amer M. Zeidan, Mikkael A. Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali,

Cassie Zimmerman, Gail J. Roboz, David P. Steensma, Amy E. DeZern, Elias Jabbour, Hagop Kantarjian, Katrina Zell, Quiqing Wang, Steven D Gore, Aziz Nazha, Jaroslaw P. Maciejewski, Alan F. List, Rami S Komrokji. “The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA).” [Oral and Poster] Blood 2014; 124:1935a.

39. Aziz Nazha, Mikkael A. Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali, Gail J.

Roboz, David P. Steensma, Amy E. DeZern, Cassie Zimmerman, Elias Jabbour, Molly D. Greenberg, Sangmin Lee, Alan F. List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Rami S Komrokji. “Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA).” [Oral and Poster] Blood 2014; 124:3273a.

40. Srinivasa Reddy Sanikommu, Michael Clemente, Peter Chomczynski, Swapna Thota, Bhumika J.

Patel, Aziz Nazha, Bartlomiej Przychodzen, Jaroslaw P. Maciejewski. “Impact of STAT3

22

Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia.” [Oral and Poster] Blood 2015; 126:2216a.

41. Bhumika J. Patel, Bartlomiej Przychodzen, Michael J. Clemente, Cassandra M. Hirsch, Tomas

Radivoyevitch, Swapna Thota, Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. “Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia.” [Oral and Poster] Blood 2015; 126:300a.

42. Aziz Nazha, Mayur Subhash Narkhede, Tomas Radivoyevitch, Matt Kalaycio, Bhumika J. Patel,

Aaron T. Gerds, Sudipto Mukherjee, Michael Clemente, Cassandra M. Hirsch, Anjali S. Advani, Bartlomiej Przychodzen, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2015; 126:607a.

43. Valeria Visconte, Steffan T. Nawrocki, Kevin R. Kelly, Yingchun Han, Anthony Possemato, Sean

Beausoleil, Aziz Nazha, Jaroslaw P. Maciejewski, Hetty E. Carraway, Anjali S. Advani, Mikkael A. Sekeres, Jennifer S. Carew. “Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy.” [Oral and Poster] Blood 2015; 126:1271a.

44. Bartlomiej Przychodzen, Xiaorong Gu, Dewen You, Cassandra M. Hirsch, Michael J. Clemente,

Aaron D. Viny, Ross L. Levine, Torsten Haferlach, Manja Maggendorfer, Mikkael A. Sekeres, Hetty E. Carraway, Aziz Nazha, Francis Enane, Jaroslaw P. Maciejewski. “PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML.” [Oral and Poster] Blood 2015; 126:1259a.

45. Aziz Nazha, Bartlomiej Przychodzen, Hideki Makishima, Hetty E. Carraway, Bhumika J. Patel,

Cassandra M. Hirsch, Michael Clemente, Srinivasa R. Sanikommu, Aaron T. Gerds, Jennifer S. Carew, Satoru Miyano, Matt Kalaycio, Seishi Ogawa, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes.” [Oral and Poster] Blood 2015; 126:611a.

46. Aziz Nazha, Bartlomiej Przychodzen, Hideki Makishima, Hetty E. Carraway, Bhumika J. Patel,

Cassandra M. Hirsch, Michael Clemente, Srinivasa R. Sanikommu, Aaron T. Gerds, Jennifer S. Carew, Satoru Miyano, Matt Kalaycio, Seishi Ogawa, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition.” [Oral and Poster] Blood 2015; 126:1645a.

47. Aziz Nazha, Ahmad Zarzour, Tomas Radivoyevitch, Hetty E. Carraway, Jennifer S. Carew,

Cassandra M Hirsch, Kassy E Kneen, Bartlomiej Przychodzen, Bhumika J. Patel, Michael Clemente, Srinivasa R. Sanikommu, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2015; 126:86a.

48. Ahmad Zarzour, Aziz Nazha, Matt Kalaycio, Bhumika J. Patel, Aaron T. Gerds, Michael J.

Clemente, Cassandra M Hirsch, Jennifer S. Carew, Anjali S. Advani, Srinivasa R. Sanikommu,

23

Bartlomiej Przychodzen, Hetty E. Carraway, Sudipto Mukherjee, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy.” [Oral and Poster] Blood 2015; 126:1319a.

49. Aziz Nazha, Rami S. Komrokji, Guillermo Garcia-Manero, John Barnard, Katrina Zell, Cassie

Zimmerman, Najla H. Al Ali, Gail J Roboz, David P. Steensma, Amy E. DeZern, Eric Padron, Elias J. Jabbour, Molly Dara Greenberg, Alan F. List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure.” [Oral and Poster] Blood 2015; 126:2888a.

50. Miguel Gallardo, Hun Ju Lee, Xiaorui Zhang, Carlos E. Bueso-Ramos, Laura Pageon, Mark

McArthur, Asha Multani, Aziz Nazha, Taghi Manshouri, Jan Parker-Thornburg, Peter Hu, Yuan Qi, Xiaoping Su, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, Joaquin Martinez-López, Sean M. Post. “hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML.” [Oral and Poster] Blood 2015; 126:439a.

51. Rafael Bejar, Elli Papaemmanuil, Torsten Haferlach, Guillermo Garcia-Manero, Jaroslaw P.

Maciejewski, Mikkael A. Sekeres, Matthew J. Walter, Timothy A. Graubert, Mario Cazzola, Luca Malcovati, Seishi Ogawa, Pierre Fenaux, Eva Hellstrom-Lindberg, Wolfgang Kern, Jacqueline Boultwood, Andrea Pellagatti, David Bowen, Sudhir Tauro, Michael J Groves, Paresh Vyas, Lynn Quek, Aziz Nazha, Felicitas Thol, Michael Heuser, Lee-Yung Shih, Eric Padron, David Sallman, Rami S. Komrokji, Alan F. List, Valeria Santini, Michaela Fontenay, Peter J Campbell, Heinz Tüchler, Kristen Stevenson, Donna S Neuberg, Peter Greenberg, Benjamin L Ebert. “Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee.” [Oral and Poster] Blood 2015; 126:907a.

52. Bartlomiej P. Przychodzen, Xiaorong Gu, Dewen You, Cassandra M. Hirsch, Michael J.

Clemente, Mikkael A. Sekeres, Aziz Nazha, Hideki Makishima, and Jaroslaw P. Maciejewski. “PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)”. [Oral and Poster] Blood 2016; 128:2736a.

53. Aaron T. Gerds, Shaloo Gupta, Gary Binder, Mikkael A. Sekeres, Aziz Nazha, Hetty E.

Carraway, Stephanie Hawthorne, Kristen King-Concialdi, Michael McGuire. “Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)”. [Oral and Poster] Blood 2016; 128:3541a.

54. Vera Adema, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Andrea Pellagatti, Jacqueline

Boultwood, Aziz Nazha, Hetty E. Carraway, Francesc Sole, Mikkael A. Sekeres, Valeria Visconte, Jaroslaw P. Maciejewski. “Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion”. [Oral and Poster] Blood 2016; 128:2007a.

55. Raffi Tchekmedyian, Paul Elson, Aaron T. Gerds, Navneet Majhail, Hetty E. Carraway, Anjali S.

Advani, Aziz Nazha, Jaroslaw P. Maciejewski, Matt Kalaycio, Mikkael A. Sekeres, Sudipto

24

Mukherjee. “Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials.” [Oral and Poster] Blood 2016; 128:4000a.

56. Suresh Kumar Balasubramanian, Mai Ali, Taha Bat, Bhumika Patel, Bartlomiej P. Przychodzen,

Cassandra M. Hirsch, Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P Maciejewski. “Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms.” Blood [Oral and Poster] 2016; 128:2872a.

57. Eiju Negoro, Michael Clemente, Naoko Hosono, Aziz Nazha, Wenyi Shen, Yasunobu Nagata,

Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Reda Z. Mahfouz, Teodora Kuzmanovic, Hideki Makishima, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. “Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome” [Oral and Poster] Blood 2016; 128:4290a.

58. Cassandra M. Hirsch, Aziz Nazha, Kassy E. Kneen, Manja Meggendorfer, Bartlomiej P.

Przychodzen, Niroshan Nadarajah, Hetty E. Carraway, Mikkael A. Sekeres, Torsten Haferlach, Thomas LaFramboise, Tomas Radivoyevitch, Jaroslaw P. Maciejewski. “Pathogenic Relevance of Germ Line TET2 Alterations.” [Oral and Poster] Blood 2016; 128:3160a.

59. Sagar S. Patel, Tomas Radivoyevitch, Aaron T. Gerds, Navneet S. Majhail, Hetty E. Carraway,

Anjali S. Advani, Aziz Nazha, Jaroslaw P. Maciejewski, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee. “Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy.” [Oral and Poster] Blood 2016; 128:2786a.

60. Vera Adema, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Aziz Nazha, Teodora

Kuzmanovic, Eiju Negoro, Dewen You, Hideki Makishima, Michael J. Clemente, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Jaroslaw P. Maciejewski. “U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts.” [Oral and Poster] Blood 2016; 128:3155a.

61. Aziz Nazha, Rami S. Komrokji, John Barnard, Najla H Al Ali, Gail J. Roboz, David P. Steensma,

Amy E. DeZern, Jaime Fensterl, Guillermo Garcia-Manero, Alan F. List, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2016; 128:4332a.

62. Bhumika Patel, Caner Saygin, Bartlomiej P. Przychodzen, Teodora Kuzmanovic, Cassandra M.

Hirsch, Michael J. Clemente, Swapna Thota, Aziz Nazha, Sekeres A. Mikkael, Jaroslaw P. Maciejewski, Hetty E. Carraway. “Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes.” [Oral and Poster] Blood 2016; 128:2002a.

63. Aziz Nazha, Mikkael A. Sekeres, Rafael Bejar, John Barnard, Karam Al-Issa, Bartlomiej P.

Przychodzen, Matt Kalaycio, Michael J. Clemente, Cassandra M. Hirsch, Benjamin L Ebert, Jaroslaw P. Maciejewski. “Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes”. [Oral and Poster] Blood 2016; 128:3193a.

25

64. Cassandra M. Hirsch, Aziz Nazha, Kassy E Kneen, Bartlomiej P. Przychodzen, Niroshan

Nadarajah, Hetty E. Carraway, Mikkael A. Sekeres, Torsten Haferlach, Tomas Radivoyevitch, Jaroslaw P. Maciejewski, Manja Meggendorfer. “Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms.” [Oral and Poster] Blood 2016; 128:4313a.

65. Bhumika Patel, Caner Saygin, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Michael J.

Clemente, Betty K. Hamilton, Anjali S. Advani, Aziz Nazha, Sarah Lynn Ondrejka, Matt Kalaycio, Mikkael A. Sekeres, Hetty E. Carraway, Jaroslaw P. Maciejewski. “Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage.” [Oral and Poster] Blood 2016; 128:1659a.

66. Karam Al-Issa, Ahmad Zarzour, Tomas Radivoyevitch, Matt Kalaycio, Betty K. Hamilton, Aaron

T. Gerds, Sudipto Mukherjee, Vera Adema, Michael J. Clemente, Bhumika Patel, Cassandra M. Hirsch, Anjali S. Advani, Bartlomiej P. Przychodzen, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Aziz Nazha. “Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best?” [Oral] Blood 2016; 128:50a.

67. Karam Al-Issa, Mikkael A. Sekeres, Alek d Nielsen, Babal Jha, Bartlomiej P. Przychodzen, Mai

Aly, Hetty E. Carraway, Anjali S. Advani, Bhumika Patel, Michael J. Clemente, Sudipto Mukherjee, Aaron T. Gerds, Jaroslaw P. Maciejewski, Aziz Nazha. “TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2016; 128:4336a.

68. Nour Abuhadra, Karam Al-Issa, Aaron T. Gerds, Sudipto Mukherjee, Bhumika Patel, Michael J.

Clemente, Vera Adema, Cassandra M. Hirsch, Anjali S. Advani, Mai Aly, Przychodzen P. Bartlomiej, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Aziz Nazha. “BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes.” [Oral and Poster] Blood 2016; 128:4293a.

69. Bhumika Patel, Bartlomiej P. Przychodzen, Michael J. Clemente, Cassandra M. Hirsch, Caner

Saygin, Marissa Versalle, Swapna Thota, Aziz Nazha, Roy Souaid, Valeria Visconte, Taha Bat, Suresh Kumar Balasubramanian, Tomas Radivoyevitch, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. “Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag.” [Oral and Poster] Blood 2016; 128:3892a.

70. Francesco Onida, Simona Iacobelli, Guillermo Garcia-Manero, Mrinal M. Patnaik, Raphaël

Itzykson, Terra L. Lasho, Aziz Nazha, Raajit K. Rampal, Matias Eugenio Sanchez, Elias J. Jabbour, Najla H Al Ali, Zachary Thompson, Simona Colla, Pierre Fenaux, Hagop M. Kantarjian, Sally Killick, Sekeres A. Mikkael, Alan F. List, Rami S. Komrokji, Ayalew Tefferi, Eric Solary, Eric Padron. “A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma.” [Oral and Poster] Blood 2016; 128:4320a.

71. Yasunobu Nagata, Hideki Makishima, Tomas Radivoyevitch, Cassandra M. Hirsch, Bartlomiej P.

Przychodzen, Teodora Kuzmanovic, Samuel Li, Kenichi Yoshida, Tetsuichi Yoshizato, Vera

26

Adema, Eiju Negoro, Michael J. Clemente, Naoko Hosono, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Sudipto Mukherjee, Aziz Nazha, Francesc Sole, Hetty E. Carraway, Satoru Miyano, Thomas LaFramboise, Mikkael A. Sekeres, Seishi Ogawa, Jaroslaw P. Maciejewski. “Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations” [Oral] Blood 2016; 128:957a.

72. Anjali S. Advani, Brenda Cooper, Paul Elson, Sudipto Mukherjee, Jaime Fensterl, Aaron T. Gerds,

Paolo F. Caimi, Ben K. Tomlinson, Ehsan Malek, Jane A. Little, Mary Lynn Rush, Samjhana Bogati, Eric Parsons, Donna Kane, Hetty E. Carraway, Aziz Nazha, Betty K. Hamilton, Ronald Sobecks, Barbara Bevier, Christopher Goebel, Cassie Zimmerman, Alek d Nielsen, Cassandra M. Hirsch, Jaroslaw P. Maciejewski, Matt Kalaycio, Marcos deLima, James Jacobberger, Philip Woost, Mikkael A. Sekeres. “A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2016; 128:4065a.

73. Vera Adema, Suresh K. Balasubramanian, Cassandra M. Hirsch, Bartlomiej P. Przychodzen,

James G Phillips, Daniel Lindner, Tomas Radivoyevitch, Sudipto Mukherjee, Aziz Nazha, Hetty E. Carraway, Francesc Sole, Mikkael A. Sekeres, Valeria Visconte and Jaroslaw P. Maciejewski. “Novel Therapeutic Targets for DNMT3EA Mutant Myeloid Neoplasms” [Oral and Poster] Blood 2017; 130:106a.

74. Anjali S. Advani, Brenda W. Cooper, Valeria Visconte, Paul Elson, E. Ricky Chan, Jennifer

Carew, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Aziz Nazha, Betty K. Hamilton, Ronald Sobecks, Paolo Caimi, Benjamin Tomlinson, Ehsan Malek, Jane A. Little, Jaime Fensterl, Allison Unger, Cassie Zimmerman, Christopher Goebel, Nita Hoxha, Caitlin Siebenaller, Jenna Thomas, Mary Lynn Rush, Samjhana Bogati, Eric Parsons, Rachael Diligente, Donna Kane, Alek Nielsen, Cassandra M. Hirsch, Simone Edelheit, Alexander Miron, John Pink, Jaroslaw P. Maciejewski, Matt Kalaycio, Marcos De Lima, Mikkael A. Sekeres. “A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed / Refractory Acute Myeloid Leukemia (AML): Final Results.” [Oral and Poster] Blood 2017; 130:150a.

75. Aziz Nazha, Mikkael A. Sekeres, Rafael Bejar, Rami S. Komrokji, John Barnard, Karam Al-Issa,

Bartlomiej P. Przychodzen, Cassandra M. Hirsch, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Benjamin L. Ebert, Jaroslaw P. Maciejewski. “Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2017; 130:157a.

76. Aziz Nazha, Rami S. Komrokji, John Barnard, Karam Al-Issa, Eric Padron, Yazan F. Madanat,

Teodora Kuzmanovic, Nour Abuhadra, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Alan F. List, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2017; 130:160a.

77. Raffi Tchekmedyian, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt

Kalaycio, Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres, Sudipto Mukherjee.

27

“Survival Among Acute Myeloid Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States.” [Oral and Poster] Blood 2017; 130:344a.

78. Raffi Tchekmedyian, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt

Kalaycio, Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres, Sudipto Mukherjee. “Survival Among Acute Lymphocytic Leukemia Patients conditional on Years Already Survived and Relative to the General Population in the United States.” [Oral and Poster] Blood 2017; 130:347a.

79. Yazan F. Madanat, Tomas Radivoyevitch, Aziz Nazha, Yazeed Sawalha, Karam Al-Issa, Nour

Abuhadra, Teodora Kuzmanovic, Bartlomiej Przychodzen, Cassandra M. Hirsch, Bhumika J. Patel, David Seastone, Yogenthiran Saunthararajah, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)” [Oral and Poster] Blood 2017; 130:424a.

80. Girish Kunapareddy, Hina Ahmed, Sagar S. Patel, Bhumika J. Patel, Paul Elson, Alicia Bitterice,

Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Alberto J. Montero, Brad Pohlman, Colleen Strazalka, Joseph Hooley, Alicia Redden, Katherine Tullio, Kimberly Bell, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee. “Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies.” [Oral and Poster] Blood 2017; 130:532a.

81. Yasunobu Nagata, Hideki Makishima, Cassandra M. Hirsch, Mai Aly, Abhinav Goyal, Hassan

Awada, Mohammad Fahad B Asad, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa, Jaroslaw P. Maciejewski. “Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS.” [Oral and Poster] Blood 2017; 130:583a.

82. Vera Adema, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Yasunobu Nagata, Elise Lemelle,

Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Jaroslaw P. Maciejewski, Richard A. Padgett. “Somatic PRPF8 Mutations in Myeloid Neoplasia.” [Oral and Poster] Blood 2017; 130:584a.

83. Mohammad Fahad B Asad, Abhinav Goyal, Hassan Awada, Mai Aly, Cassandra Hirsch, Michael

J. Clemente, Aziz Nazha, Hetty E. Carraway, Sudipto Mukherjee, Yasunobu Nagata, Jaroslaw P. Maciejewski. “Extent and Clinical Implications of Subclonal Diversity n Paroxysmal Nocturnal Hemoglobinuria.” [Oral and Poster] Blood 2017; 130:779a.

84. Edward F. Greenberg, Cassandra M. Hirsch, Shi Chen, Xiaochen Liiu, Babal K. Jha, Valeria

Visconte, Dewen You, Bartlomiej P. Przychodzen, Thomas Laframboise, Hideki Makishima, Aziz Nazha, Mingjiang Xu, Daniel Gackowski, Mridul Mukherji, Mikkael A. Sekeres, Ryszard Ólinski, Jaroslaw P. Maciejewski. “Modulation of TET2 Activity with Ascorbic Acid in Myeloid Neoplasia: Diagnostic and Therapeutic Implications.” [Oral and Poster] Blood 2017; 130:1205a.

28

85. Aziz Nazha, Sudipto Mukherjee, Karam Al-Issa, Ahed Makhoul, Vera Adema, Cassandra M. Hirsch, Anjali S. Advani, Aaron T. Gerds, Matt Kalaycio, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. “A personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2017; 130:1408a.

86. Aziz Nazha, Mikkael A. Sekeres, Karam Al-Issa, Ahed Makhoul, Vera Adema, Cassandra M.

Hirsch, Anjali S. Advani, Bartlomiej P. Przychodzen, Teodora Kuzmanovic, Babal K Jha, Aaron T. Gerds, Hetty E. Carraway, Sudipto Mukherjee, Matt Kalaycio, Jaroslaw P. Maciejewski. “Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype.” [Oral and Poster] Blood 2017; 130:1409a.

87. Teodora Kuzmanovic, Tomas Radivoyevitch, Srinivasa Reddy Sanikommu, Bhumika J. Patel,

Yasunobu Nagata, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski. “Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease.” [Oral and Poster] Blood 2017; 130:1673a.

88. Bhumika J. Patel, Sagar S. Patel, Tomas Radivoyevitch, Swapna Thota, Teodora Kuzmanovic,

Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Donna M. Abounader, Aziz Nazha, Sudipto Mukherjee, Aaron T. Gerds, Anjali S. Advani, Brian J. Bolwell, Matt Kalaycio, Mikkael A. Sekeres, Ronald Sobecks, Hetty E. Carraway, Navneet S. Majhail, Betty K. Hamilton, Jaroslaw P. Maciejewski. “Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation.” [Oral and Poster] Blood 2017; 130:1682a.

89. Metis Hasipek, Sayer Al-Harbi, James G. Phillips, Bartlomiej P. Przychodzen, Alek Nielsen,

Yihong Guan, Dale Grabowski, Phillip J Maciejewski, Aziz Nazha, Hetty E. Carraway, Jaroslaw P. Maciejewski, Babal K. Jha. “Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia.” [Oral and Poster] Blood 2017; 130:2654a.

90. Caner Saygin, Cassandra M. Hirsch, Bartlomiej Przychodzen, Mikkael A. Sekeres, Betty K.

Hamilton, Matt Kalaycio, Hetty E. Carraway, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Ronald Sobecks, Christopher Goebel, Donna M. Abounader, Jaroslaw P. Maciejewski, Anjali S. Advani. “Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate – Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1.” [Oral and Poster] Blood 2017; 130:2665a.

91. Yazeed Sawalha, Paul Elson, Yazan F. Madanat, Nicole Droz, Apostolos Kontzias, Teodora

Kuzmanovic, Cassandra M. Hirsch, Christopher Goebel, John Desamito, Benjamin Tomlinson, Aziz Nazha, Ronald Sobecks, Betty K. Hamilton, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Anjali S. Advani. “Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease.” [Oral and Poster] Blood 2017; 130:2670a.

92. Remco J Molenaar, Tomas Radivoyevitch, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds,

Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres, Matt Kalaycio, Sudipto Mukherjee. “Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors.” [Oral and Poster] Blood 2017; 130:2871a.

29

93. Lilian Iglesias, Sudipto Mukherjee, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres. “No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).” [Oral and Poster] Blood 2017; 130:2872a.

94. Olivia Copelan, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Navneet S.

Majhail, Mikkael A. Sekeres, Matt Kalaycio, Sudipto Mukherjee. “Association of Tyrosine Kinase Inhibitors with Vascular Adverse Events: A Cohort Study Using Pooled Electronic Health Record.” [Oral and Poster] Blood 2017; 130:2877a.

95. Aziz Nazha, Abhinav Goyal, Mohammad Fahad B. Asad, Hassan Awada, Mai Aly, Cassandra M.

Hirsch, Bartlomiej P. Przychodzen, Tomas Radivoyevitch, Sudipto Mukherjee, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Yasunobu Nagata. “How Somatic Mutations Carve Morphologic Imprint in MDS?” [Oral and Poster] Blood 2017; 130:2949a.

96. Jack Khouri, Vera Adema, Ying Ni, Heesun J. Rogers, Bartlomiej P. Przychodzen, Cassandra M.

Hirsch, Elise Lemelle, Teodora Kuzmanovic, Anjali S. Advani, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Yogenthiran Saunthararajah, Yazan F. Madanat, Bhumika J. Patel, Francesc Sole, Steffan T. Nawrocki, Jennifer Carew, Matt Kalaycio, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Valeria Visconte, Hetty E. Carraway. “Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations.” [Oral and Poster] Blood 2017; 130:2961a.

97. Karam Al-Issa, Yazan F. Madanat, Sudipto Mukherjee, Cassandra M. Hirsch, Aaron T. Gerds,

Nour Abuhadra, Ahed Makhoul, Hassan Awada, Mohammad Fahad B Asad, Abhinav Goyal, Anjali S. Advani, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Aziz Nazha. “Model Heterogeneity in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2017; 130:2972a.

98. Aziz Nazha, Betty K. Hamilton, Mikkael A. Sekeres, Sudipto Mukherjee, Aaron T. Gerds, Rabi

Hanna, Cassandra M. Hirsch, Teodora Kuzmanovic, Karam Al-Issa, Bartlomiej P. Przychodzen, Ronald Sobecks, Matt Kalaycio, Navneet S. Majhail, Jaroslaw P. Maciejewski. “Mutational Burden before and after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML).” [Oral and Poster] Blood 2017; 130:3272a.

99. Caner Saygin, Ryan D. Cassaday, Natalie Reizine, Ilana Yurkiewicz, Michaela Liedtke, Wendy

Stock, Richard A. Larson, Cassandra M. Hirsch, Bartlomiej Przychodzen, Mikkael A. Sekeres, Matt Kalaycio, Hetty E. Carraway, Betty K. Hamilton, Ronald Sobecks, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Donna M. Abounader, Jaroslaw P. Maciejewski, Anjali S. Advani. “Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia.” [Oral and Poster] Blood 2017; 130:3993a.

100. Cassandra M. Hirsch, Aziz Nazha, Kneen Kassy, Manja Meggendorfer, Bartlomiej P.

Przychodzen, Niroshan Nadarajah, Vera Adema, Yasunobu Nagata, Valeria Visconte, Hetty E. Carraway, Mikkael A. Sekeres, Ryszard Ólinski, Sudipto Mukherjee, Babal K Jha, Thomas Laframboise, Tomas Radivoyevitch, Torsten Haferlach, Jaroslaw P. Maciejewski. “Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms.” [Oral and Poster] Blood 2017; 130:4228a.

30

101. Reem Elagooz, Mai Aly, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Teodora Kuzmanovic,

Tomas Radivoyevitch, Valeria Visconte, Sudipto Mukherjee, Hetty E. Carraway, Mikkael A. Sekeres, Aziz Nazha, Jaroslaw P. Maciejewski, Yasunobu Nagata. “PPMD1D Mutations and up Modulation Phenocopy TP53 Lesions in Myeloid Neoplasms.” [Oral and Poster] Blood 2017; 130:4233a.

102. Yazan F. Madanat, Mikkael A. Sekeres, Karam Al-Issa, Cassandra M. Hirsch, Sudipto Mukherjee,

Aaron T. Gerds, Nour Abuhadra, Babal K Jha, Vera Adema, Anjali S. Advani, Yasunobu Nagata, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Hetty E. Carraway, Jaroslaw P. Maciejewski, Aziz Nazha. “Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS).” [Oral and Poster] Blood 2017; 130:4245a.

103. Rami S. Komrokji, Najla Al Ali, John Barnard, David P. Steensma, Amy E. DeZern, Gail J.

Roboz, David A. Sallman, Eric Padron, Aziz Nazha, Alan F. List, Guillermo Garcia-Manero, Mikkael A. Sekeres. “Outcomes of Myelodysplastic Syndromes (MDS) Patients with Chromosome 17 Abnormalities: A Report on Behalf of the MDS Clinical Research Consortium (MDSCRC).” [Oral and Poster] Blood 2017; 130:4246a.

104. Aziz Nazha, Mrinal M. Patnaik, Rami S. Komrokji, Karam Al-Issa, Naval Daver, Guillermo

Garcia-Manero, Jaroslaw P. Maciejewski, Alan F. List, Michael R. Savona, Raphael Itzykson, Pierre Fenaux, Valeria Santini, Ayalew Tefferi, Mikkael A. Sekeres, Eric Padron. “Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower- Risk Group.” [Oral and Poster] Blood 2017; 130:4255a.

105. Christopher B Benton, Maliha Khan, Graciela Nogueras González, Aziz Nazha, Jin Piao, Jing

Ning, Fleur M. Aung, Elias J. Jabbour, Tapan Kadia, Gautam Borthakur, Farhad Ravandi, Rami S. Komrokji, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Mikkael A. Sekeres, Michael Andreeff, Hagop M. Kantarjian, Guillermo Garcia-Manero. “Sequential Stratification Prognostic Score for Patients with Intermediate – Risk Myelodysplastic Syndrome.” [Oral and Poster] Blood 2017; 130:4265a.

106. Yasunobu Nagata, Hideki Makishima, Tetsuichi Yoshizato, Hiromichi Suzuki, Cassandra M.

Hirsch, Abhinav Goyal, Hassan Awada, Mohammad Fahad B. Asad, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa and Jaroslaw P. Maciejewski. “Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS).” [Oral] Blood 2018; 132:104.

107. Aziz Nazha, Zhen-Huan Hu, Tao Wang, Betty K. Hamilton, Navneet S. Majhail, R. Coleman

Lindsley, Ronald Sobecks, Uday Popat, Bart L Scott and Wael Saber. “A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee.” [Oral] Blood 2018; 132-206a.

31

108. Raffi Tchekmedyian, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway, Anjali S. Advani, Jaroslaw P. Maciejewski, Matt Kalaycio, Navneet S. Majhail, Mikkael A. Sekeres and Sudipto Mukherjee. “Survival Outcomes of Patients with Therapy – Related Myelodysplastic Syndromes in the United States.” [Oral] Blood 2018; 132:371a.

109. Madeline Waldron, Caitlin Siebenaller, Marc Earl, Hetty E. Carraway, Anjali S. Advani, Aziz

Nazha, Aaron T. Gerds, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Barb Tripp, Brian P. Hobbs, Sudipto Mukherjee and Mikkael A. Sekeres. “Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety.” [Oral] Blood 2018; 132:712a.

110. Aziz Nazha, Rami S. Komrokji, Manja Meggendorfer, Sudipto Mukherjee, Najla Al Ali, Wencke

Walter, Stephan Hutter, Eric Padron, Yazan F. Madanat, David A Sallman, Teodora Kuzmanovic, Cassandra M. Hirsch, Vera Adema, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Alan F. List, Claudia Haferlach, Jaroslaw P. Maciejewski, Torsten Haferlach and Mikkael A. Sekeres. “A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes.” [Oral] Blood 2018; 132:793a.

111. Remco J Molenaar, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway,

Anjali S. Advani, Matt Kalaycio, Navneet S. Majhail, Jaroslaw P. Maciejewski, Mikkael A. Sekeres and Sudipto Mukherjee. “Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?” [Oral] Blood 2018; 132:900a.

112. Swapna Thota, Bhumika J. Patel, Hetty E. Carraway, Elizabeth A. Griffiths, Amanda

Przespolewski, James E. Thompson, Teodora Kuzmanovic, Aziz Nazha, Shimoli Vipul Barot, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, Meghan Scully, Aaron T. Gerds, Anjali S. Advani, Mikkael A. Sekeres, Manja Meggendorfer, Eunice S. Wang and Jaroslaw P. Maciejewski. “Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/ 2mutations after Intensive Chemotherapy.” [Poster] Blood 2018; 132:1389a.

113. Rachel Hu, Aziz Nazha, Xuefei Jia, Brian P. Hobbs, Hetty E. Carraway, Sudipto Mukherjee,

Aaron T. Gerds, Anjali S. Advani, Yasunobu Nagata, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Babal K. Jha, Jaroslaw P. Maciejewski and Mikkael A. Sekeres. “Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia.” [Poster] Blood 2018; 132:1527a.

114. Yazan F. Madanat, Mikkael A. Sekeres, Sudipto Mukherjee, Cassandra M. Hirsch, Yihong Guan,

Yasunobu Nagata, Vera Adema, Metis Hasipek, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Bartlomiej P. Przychodzen, Valeria Santini, Jaroslaw P. Maciejewski, Babal K. Jha and Aziz Nazha. “Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes.” [Poster] Blood 2018; 132:1797a.

115. Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad Fahad B. Asad, Bhumika J. Patel,

Cassandra M. Hirsch, Teodora Kuzmanovic, Vera Adema, Mai Aly, Bartlomiej P. Przychodzen, Yihong Guan, Wenyi Shen, Louis Williams, Aziz Nazha, Mohamed Abazeed, Mikkael A. Sekeres, Tomas Radivoyevitch, Torsten Haferlach, Babal K. Jha, Valeria Visconte and Jaroslaw P. Maciejewski. “Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes.” [Poster] Blood 2018; 132:1805a.

32

116. C. Beau Hilton, Mikkael A. Sekeres, Manja Meggendorfer, Wencke Walter, Stephan Hutter, Eric Padron, Michael R. Savona, Aaron T. Gerds, Yihong Guan, David A Sallman, Sudipto Mukherjee, Mrinal M. Patnaik, Brianna Smith, Yasunobu Nagata, Vera Adema, Metis Hasipek, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Rami S. Komrokji, Babal K. Jha, Claudia Haferlach, Jaroslaw P. Maciejewski, Torsten Haferlach and Aziz Nazha. “Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML).” [Oral] Blood 2018; 132-1813a.

117. Abhinav Goyal, Inom Mirzaev, Mohammad Fahad B. Asad, Hassan Awada, Cassandra M. Hirsch,

Hideki Makishima, Kenichi Yoshida, Bartlomiej P. Przychodzen, Aziz Nazha, Sudipto Mukherjee, Mikkael A. Sekeres, Seishi Ogawa, Tomas Radivoyevitch, Jacob Scott, Jaroslaw P. Maciejewski and Yasunobu Nagata. “Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS).” [Poster] Blood 2018; 132:1824a.

118. Sagar S. Patel, Betty K. Hamilton, Lisa Rybicki, Dawn Thomas, Arden Emrick, Aziz Nazha,

Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Brad Pohlman, Brian J. Bolwell, Robert M. Dean, Aaron T. Gerds, Rabi Hanna, Matt Kalaycio, Aiwen Zhang, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Navneet S. Majhail, Medhat Askar and Ronald Sobecks. “Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia.” [Poster] Blood 2018; 132:2075a.

119. Sophia Colombari Figueroa, Bhumika J. Patel, Shimoli Vipul Barot, Teodora Kuzmanovic, Aziz

Nazha, Eric D. Hsi, James R. Cook, Sudipto Mukherjee, Aaron T. Gerds, Mikkael A. Sekeres, Matt Kalaycio, Anjali S. Advani, Jaroslaw P. Maciejewski and Hetty E. Carraway. “TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer.” [Poster] Blood 2018; 132:2270a.

120. Raffi Tchekmedyian, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway,

Anjali S. Advani, Jaroslaw P. Maciejewski, Matt Kalaycio, Navneet S. Majhail, Mikkael A. Sekeres and Sudipto Mukherjee. “Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States.” [Poster] Blood 2018; 132:2298a.

121. Yasunobu Nagata, Hideki Makishima, Cassandra M. Hirsch, Hassan Awada, Abhinav Goyal,

Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Tetsuichi Yoshizato, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa and Jaroslaw P. Maciejewski. “Distinct Features of Chip-Derived and De Novo MDS.” [Poster] Blood 2018; 132:2572a.

122. Aziz Nazha, Manja Meggendorfer, Sudipto Mukherjee, Wencke Walter, Stephan Hutter, Ahed

Makhoul, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Hetty E. Carraway, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal K. Jha, Jaroslaw P. Maciejewski, Claudia Haferlach, Mikkael A. Sekeres and Torsten Haferlach. “Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype.” [Poster] Blood 2018; 132:2809a.

123. Cassandra M. Hirsch, Wenyi Shen, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema,

Teodora Kuzmanovic, Louis Williams, Aziz Nazha, Valeria Visconte, Hetty E. Carraway,

33

Mikkael A. Sekeres and Jaroslaw P. Maciejewski. “Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS.” [Poster] Blood 2018; 132:3074a.

124. Teodora Kuzmanovic, Bhumika J. Patel, Srinivasa Reddy Sanikommu, Yasunobu Nagata, Hassan

Awada, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Remco J Molenaar, Babal K. Jha, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski and Tomas Radivoyevitch. “Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential.” [Poster] Blood 2018; 132:3084a.

125. Sudipto Mukherjee, Tomas Radivoyevitch, Brian P. Hobbs, Xuefei Jia, Rami S. Komrokji, David

P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Jaroslaw P. Maciejewski, Aziz Nazha, and Mikkael A. Sekeres. “Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA.” [Poster] Blood 2018; 132:3095a.

126. Sudipto Mukherjee, David P. Steensma, Rami S. Komrokji, Amy E. DeZern, Gail J. Roboz,

Guillermo Garcia-Manero, Aziz Nazha, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Brian P. Hobbs and Xuefei Jia. “Does Trial Participation Improve Outcomes for Highter-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?” [Poster] Blood 2018; 132:3096a.

127. Sudipto Mukherjee, David P. Steensma, Rami S. Komrokji, Amy E. DeZern, Gail J. Roboz,

Guillermo Garcia-Manero, Aziz Nazha, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Brian P. Hobbs and Xuefei Jia. “What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?” [Poster] Blood 2018; 132:3098a.

128. Bhumika J. Patel, Shimoli Vipul Barot, Bartlomiej P. Przychodzen, Teodora Kuzmanovic,

Michael Clemente, Cassandra M. Hirsch, Valeria Visconte, Roy Souaid, Marissa Versalle, Sarah S Lee, Tomas Radivoyevitch, Metis Haspiek, Swapna Thota, Aziz Nazha, Matt Kalaycio, Anjali S. Advani, Hetty E. Carraway, Mikkael A. Sekeres and Jaroslaw P. Maciejewski. “Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia.” [Poster] Blood 2018; 132:3869a.

129. Yihong Guan, Anand D. Tiwari, Metis Hasipek, Dale Grabowski, Yvonne Parker, Cassandra M.

Hirsch, Amy C Graham, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, Tomas Radivoyevitch, James G Phillips, Jaroslaw P. Maciejewski and Babal K. Jha. “Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases.” [Poster] Blood 2018; 132-4345a.

130. Yihong Guan, Edward F Greenberg, Metis Hasipek, Cassandra M. Hirsch, Amy C Graham, Tomas

Radivoyevitch, Shi Chen, Xiaochen Liu, Valeria Visconte, Dewen You, Eiju Negoro, Bartlomiej P. Przychodzen, Hideki Makishima, Aziz Nazha, Daniel Gackowski, Ewelina Zarakowska, Mridul Mukherji, Mikkael A. Sekeres, Mingjiang Xu, Ryszard Ólinski, Jaroslaw P. Maciejewski and Babal K. Jha. “Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation.” [Poster] Blood 2018; 132:4346a.

34

131. Louis Williams, Teodora Kuzmanovic, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Yogenthiran Saunthararajah, Hassan Awada, Vera Adema, Amy C Graham, Tomas Radivoyevitch, Hetty E. Carraway, Aziz Nazha, Mikkael A. Sekeres and Jaroslaw P. Maciejewski. “BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden.” [Poster] Blood 2018; 132:4352a.

132. Teodora Kuzmanovic, Bhumika J. Patel, Yasunobu Nagata, Hassan Awada, Cassandra M. Hirsch,

Bartlomiej P. Przychodzen, Srinivasa Reddy Sanikommu, Louis Williams, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Tomas Radivoyevitch, Hetty E. Carraway, Mikkael A. Sekeres and Jaroslaw P. Maciejewski. “Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML.” [Poster] Blood 2018; 132:4353a.

133. Vera Adema, Cassandra M. Hirsch, Bartlomiej Przychodzen, Yasunobu Nagata, Tomas

Radivoyevitch, Thomas Laframboise, Amy C Graham, Louis Williams, Hassan Awada, Aziz Nazha, Hetty E. Carraway, Valeria Santini, Hrishikesh M Mehta, Francesc Sole, Mikkael A. Sekeres, Valeria Visconte, Rabi Hanna, Seth J. Corey and Jaroslaw P. Maciejewski. “Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutation.” [Poster] Blood 2018; 132:4389a.

134. Sagar S. Patel, Betty K. Hamilton, Lisa Rybicki, Dawn Thomas, Arden Emrick, Aziz Nazha,

Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Brad Pohlman, Brian J. Bolwell, Robert M. Dean, Aaron T. Gerds, Rabi Hanna, Matt Kalaycio, Aiwen Zhang, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Navneet S. Majhail, Medhat Askar and Ronald Sobecks. “Risk Factors for Early Relapse after allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia.” [Poster] Blood 2018; 132:4603a.

135. Madeline Waldron, Caitlin Siebenaller, Brian P. Hobbs, Marc Earl, Mary Schleicher, Hetty E.

Carraway, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Mikkael A. Sekeres and Sudipto Mukherjee. “Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis.” [Poster] blood 2018; 132:4805a.

136. Madeline Waldron, Caitlin Siebenaller, Marc Earl, Xuefei Jia, Hetty E. Carraway, Anjali S.

Advani, Aziz Nazha, Aaron T. Gerds, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Barb Tripp, Brian P. Hobbs, Mikkael A. Sekeres and Sudipto Mukherjee. “Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay.” [Poster] Blood 2018; 132:4806a.